High dose chemotherapy - Costs of high-dose chemotherapy and peripheral blood progenitor cell autograft for breast cancer

The aim of the study was to analyze the real cost of single or tandem high- dose chemotherapy (HDC) and peripheral blood progenitor cell autologous tra nsplant (PBPCT) in patients with breast cancer. We analyzed the costs of 40 PBPCT performed in 20 patients. Tandem transplant was planned for each pat ient. Resources used and direct costs were identified for each patient. The study was carried out using the hospital perspective and monetary values w ere reported in 1999 Euro, The mean cost of whole procedure for single tran splant was 20816.63 Euro, while the mean cost of tandem transplant was 3877 0.83 Euro. The cost distribution in the two groups was similar: the most ex pensive phase of procedure was the supportive phase post transplant (about 60% of total cost), with the categories of cost most represented being prof essional fees (about 28%) and pharmacy (about 35%), Awaiting more convincin g trials of the clinical advantage of HDC in breast cancer, our analytical evaluation of transplant costs for different therapeutic options, single or tandem, permits identification of the most expensive categories in order t o intervene for cost savings.